Recombinant Human FVIII Protein
Syd Labs Recombinant Human FVIII Protein BP000037-GD12, The potency per mg of recombinant human FVIII protein was tested and found to be 11,000 Units/mg.
- 产品参数
- 文献
- More Offers
| 货号 | BP000037-GD12 |
|---|---|
| 产品名称 | Recombinant Human FVIII Protein |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | 悉得（Syd Labs） |
| 别称 | Coagulation Factor VIII |
| 来源 | 293 cell-derived. |
| 形式 | Lyophilized from a 0.2 um filtered solution of 27 ug/ml sodium chloride, 3.0 ug/ml sucrose, 1.5 ug/ml L-histidine, 0.25 ug/ml calcium chloride dihydrate, and 0.1 ug/ml polysorbate 80, pH 6.8. Reconstitution: Reconstitute at 1 ug/ml in sterile H2O. |
| 纯度 | > 95%, by SDS-PAGE under reducing conditions and visualized by silver stain. |
| 内毒素 | <1.0 EU per 1 ug of the protein by the LAL method. |
| 运输 | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| 注意事项 | Conditions of optimal FVIII Protein performance should be determined experimentally by the investigator. |
| 线下下单 | 电话: 18162660842微信: duozhaozhao_2017Email: message@sydlabs.comOr 联系我们 |
描述
BP000037-GD12: Recombinant Human FVIII Protein
Background
Coagulation factor VIII (FVIII) is an essential blood clotting factor also known as anti-hemophilic factor (AHF). In humans, FVIII is encoded by the F8 gene(1-2). Defects in this gene results in hemophilia A, a well known recessive X-linked coagulation disorder(3). Factor VIII participates in blood coagulation; it is a cofactor for factor IXa which, in the presence of Ca+2 and phospholipids forms a complex that converts factor X to the activated form Xa. FVIII is processed from a single-chain polypeptide having the domain structure A 1 -A2-B-A3-C 1 -C2. The heavy chain is composed of domains Al-A2-B while the light chain is composed of domains A3-Cl-C2. The B domain is extensively glycosylated on asparagine, serine, and threonine residues(4). Initial studies showed that deletion of the B domain resulted in a functional molecule as tested by in vitro assays and was expressed more efficiently compared with wildtype FVIII(5).
References:
1. Toole JJ, Knopf JL, et al. (1984). Nature 312 (5992): 342?.
2. Truett MA, Blacher R, et al. (1985). DNA 4 (5): 333?9.
3. Antonarakis SE (1995). Haemost. 74 (1): 322?.
4. Vehar GA, Keyt B, et al. (1984). Nature 312:337.
5. Toole JJ, Pittman DD, et al. (1986) Proc Natl Acad Sci USA 835939.
BP000037-GD12: Recombinant Human FVIII Protein
Source: 293 cell-derived.
Ala20-Gsn764, Pro1659-Ly2351, Accession# NP_000123
N-terminal sequence analysis: Ala
Predicted molecular mass: 170 kDa
SDS-PAGE: 96 kDa, reducing conditions
The potency per mg of recombinant human FVIII protein was tested and found to be 11,000 Units/mg.
Endotoxin Level: <1.0 EU per 1 ug of the protein by the LAL method.
Purity > 95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Formulation: Lyophilized from a 0.2 um filtered solution of 27 ug/ml sodium chloride, 3.0 ug/ml sucrose, 1.5 ug/ml L-histidine, 0.25 ug/ml calcium chloride dihydrate, and 0.1 ug/ml polysorbate 80, pH 6.8.
Reconstitution: Reconstitute at 1 ug/ml in sterile H2O.
Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month, 2 to 8°C under sterile conditions after reconstitution.
3 months, -20 to -70°C under sterile conditions after reconstitution.
Please remember our product information: Recombinant Human FVIII Protein: BP000037-GD12 Syd Labs